Oliver Luxxe Assets LLC Has $1.97 Million Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

Oliver Luxxe Assets LLC decreased its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 24.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,738 shares of the specialty pharmaceutical company’s stock after selling 7,782 shares during the period. Oliver Luxxe Assets LLC’s holdings in ANI Pharmaceuticals were worth $1,965,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ANIP. KBC Group NV acquired a new position in shares of ANI Pharmaceuticals during the first quarter worth $28,000. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at $28,000. Hantz Financial Services Inc. grew its position in ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in ANI Pharmaceuticals during the 4th quarter worth $48,000. Finally, State of Wyoming acquired a new position in ANI Pharmaceuticals in the 2nd quarter worth about $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Thomas Andrew Rowland sold 459 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total transaction of $36,357.39. Following the completion of the sale, the senior vice president owned 38,271 shares of the company’s stock, valued at approximately $3,031,445.91. This represents a 1.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the transaction, the director owned 38,878 shares of the company’s stock, valued at approximately $3,144,452.64. The trade was a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 88,029 shares of company stock valued at $6,954,472 over the last three months. Insiders own 8.10% of the company’s stock.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Second-quarter adjusted earnings per share were $2.21, exceeding the roughly $2.01-$2.04 consensus range, while revenue of $266.0 million surpassed estimates near $260 million. Revenue increased 25.9% year over year, and adjusted EBITDA rose 32.4% to $71.6 million. ANI Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Purified Cortrophin Gel revenue climbed 43.5% to $117.1 million. Management said the expansion into podiatrists and primary-care physicians for acute gout was fully operational by June, with encouraging early prescribing and patient-case trends. ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
• Positive Sentiment: ANI reaffirmed full-year 2026 revenue guidance of $1.08 billion-$1.14 billion, adjusted EBITDA of $285 million-$300 million and adjusted EPS of $9.19-$9.69, above the prior consensus EPS estimate of $9.10. The company also has authorization for up to $100 million in share repurchases through May 2029. ANI Pharmaceuticals Reports Second-Quarter 2026 Results
• Neutral Sentiment: Generics revenue increased 9.7% to $99.1 million, supported by new launches, while ANI reported 12 generic launches year to date and remains on track for at least 15 in 2026.
• Negative Sentiment: ANI reduced its 2026 Cortrophin Gel revenue target to $520 million-$540 million from $540 million-$575 million. Although the revised range still implies 50%-55% growth, the cut may have disappointed investors expecting stronger near-term performance.
• Negative Sentiment: Gross margin fell to 62.4% from 64.7%, partly because of a greater mix of royalty-bearing products. Selling, general and administrative costs rose 12.1% as ANI expanded its rare-disease sales force for the gout opportunity.
• Negative Sentiment: ILUVIEN revenue declined 16.1% to $18.7 million because of international shipment timing, while Brands revenue fell 10.5% amid normalized demand.

Analyst Upgrades and Downgrades

ANIP has been the subject of several research reports. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Guggenheim reissued a “buy” rating and set a $124.00 target price on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Finally, Canaccord Genuity Group initiated coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 16th. They set a “hold” rating and a $91.00 price target for the company. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $106.83.

ANI Pharmaceuticals Stock Down 5.3%

Shares of ANIP opened at $78.25 on Friday. The stock’s 50-day moving average price is $81.02 and its two-hundred day moving average price is $79.37. ANI Pharmaceuticals, Inc. has a 12 month low of $70.15 and a 12 month high of $99.50. The company has a market capitalization of $1.78 billion, a PE ratio of 16.86 and a beta of 0.44. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. During the same quarter in the prior year, the firm posted $1.80 earnings per share. The business’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.